Naloxone cuts opioid-related ED visits in half, and community availability cuts overdose deaths. Learn about increasing access to naloxone through co-prescribing, community distribution, and pharmacy furnishing.
Naloxone is a safe and effective antidote for opioid overdose that works by temporarily blocking opioid receptors. Data is accumulating that making naloxone widely available can cut overdose deaths. The CDC now recommends offering naloxone to patients on higher doses of opioids or with other risk factors for opioid overdose. A recent study published in Annals of Internal Medicine found that co-prescribing naloxone resulted in 47% fewer opioid-related ED visits in the first year after receiving the prescription.
Learn more about this groundbreaking research from Dr. Phillip Coffin of the San Francisco Department of Public Health. This webinar also offers background on new formulations and regulatory issues surrounding naloxone from pharmacist James Gasper. Finally, Dr. Gary Tsai from the SafeMedLA coalition shares successes and challenges in increasing naloxone access in Los Angeles County.
This webinar features:
- Phillip Coffin, MD, director of substance use research at the San Francisco Department of Public Health
- James Gasper, PharmD, BCPP, psychiatric and substance use disorder pharmacist at California Department of Health Care Services
- Gary Tsai, MD, medical director and science officer, Substance Abuse Prevention and Control for the County of Los Angeles' Department of Public Health
A recording of the event and the presentation slides are available below.